Connect with us

News

Elon Musk shares details about Tesla’s mRNA microfactories for CureVac

(Credit: CureVac)

Published

on

Elon Musk shared some details about Tesla’s mRNA microfactories for CureVac’s COVID vaccine development recently. In February 2019, CureVac published a press release that referred to a bioreactor dubbed The RNA Printer. Musk’s recent tweet provided some details about the bioreactor Tesla developed for CureVac’s mRNA vaccine initiatives. 

“Tesla makes the RNA Bioreactor that can make vaccines/cures. Curevac has Version 2 in use. Version 3 is under development.  I do expect this to become an important product for the world, but probably not financially for Tesla,” Musk stated on Twitter as a response to an inquiry from Tesla owner-investor @SamTalksTesla.

Musk discussed Tesla’s partnership with CureVac in July 2020 and shared his thoughts about the potential of synthetic RNA and DNA. At the time, Musk referred to diseases as a “software problem.” With that perspective, Tesla seems more than capable of developing technology to manufacture mRNA vaccines at scale. Musk visited CureVac’s headquarters in Tübingen, Germany in September to discuss Tesla subsidiary Grohmann Automation’s contribution to the development of CureVac’s mRNA COVID vaccine.

mRNA vaccines are easier to produce and scale compared to traditional ones. Tesla’s RNA Bioreactor will come into play during the production stage of CureVac’s COVID vaccine, once it is approved. Due to the scalability of mRNA vaccines, Tesla’s RNA Bioreactor might play a key role in making CureVac’s COVID vaccine easily accessible to the public. 

Last week, CureVac reported positive results in Phase 1 of its COVID vaccine candidate. “We are very encouraged by the interim Phase 1 data. It represents a critical milestone in our COVID-19 vaccine program and strongly supports the advancement of our vaccine candidate,” said Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.

Advertisement

“Following further data readouts and discussion with regulatory authorities, we remain fully committed and on track to initiate a pivotal Phase 2b/3 trial before the end of 2020,” he added.

As of this writing, there have been no mRNA vaccines licensed for infectious disease because they are relatively new in the world of medicine. This new type of vaccine allows scientists to create synthetic mRNA, which contains the code for infectious proteins that create a virus’ molecules. 

Vaccines that make synthetic mRNA cannot form a full virus, but it can develop enough of its parts to trigger the body’s immune system. The human body has innate immunity, which are defense systems we are born with, and acquired immunity, which develops over time as we come into contact with pathogens. Traditional vaccines work more with the acquired immune system, while mRNA vaccines have the potential to trigger the body’s innate immune system. Since it is incapable of developing full viruses, mRNA vaccine patients cannot spread the disease either. 

Maria--aka "M"-- is an experienced writer and book editor. She's written about several topics including health, tech, and politics. As a book editor, she's worked with authors who write Sci-Fi, Romance, and Dark Fantasy. M loves hearing from TESLARATI readers. If you have any tips or article ideas, contact her at maria@teslarati.com or via X, @Writer_01001101.

Advertisement
Comments

News

Neuralink Blindsight human trials expected to start in the UAE

Neuralink aims to restore vision with its Blindsight BCI implant. First human implant for Blindsight may happen in UAE.

Published

on

Neuralink-clinical-trial-recruit-patient-prime-study
(Credit: Neuralink)

During Elon Musk’s interview at the Qatar Economic Forum, he announced that Neuralink aims to implant its Blindsight brain-to-computer interface (BCI) device in a human patient by late 2025 or early 2026.

Blindsight focuses on restoring vision. A few years ago, Musk mentioned that Neuralink’s BCI devices would restore vision for people, even those born blind.

“The first two applications we’re going to aim for in humans are restoring vision, and I think this is notable in that even if someone has never had vision ever, like they were born blind, we believe we can still restore vision. The visual part of the cortex is still there. Even if they’ve never seen before, we’re confident they could see,” Musk said during Neuralink’s Show & Tell in 2022. 

Musk said Blindsight could be implanted into a human patient in the United Arab Emirates (UAE). Neuralink plans to partner with the Cleveland Clinic Abu Dhabi to implant the first human patient with Blindsight.

Advertisement

Elon Musk’s neurotechnology company is partnering with the Cleveland Clinic Abu Dhabi to conduct the first clinical trial of the UAE-PRIME study. Like Neuralink’s PRIME study in the United States, UAE-PRIME will focus on human patients with motor and speech impairments.

Neuralink received Food and Drug Administration (FDA) approval to conduct the PRIME and CONVOY studies in the United States. PRIME tests the capabilities of the company’s Link implant to restore or enable motor and speech in participants. Meanwhile, the CONVOY study explores Link’s ability to control assistive robotic devices. Neuralink already has an assistive robotic arm called ARA that could expand patients’ autonomy beyond smart devices.

Blindsight would probably require a separate study from PRIME and CONVOY. As such, Neuralink might need FDA approval in the United States to start human trials for Blindsight. However, Blindsight already received a “breakthrough device” designation from the US FDA.

In April 2025, Neuralink opened its patient registry to participants worldwide. The neurotechnology company has already implanted its Link BCI device into five patients. Earlier this year, Neuralink welcomed one of its first PRIME study participants as the first patient in its CONVOY study.

Continue Reading

Elon Musk

Elon Musk just revealed more about Tesla’s June Robotaxi launch

Tesla CEO Elon Musk gave more information about the Robotaxi launch in Austin set for June.

Published

on

elon musk
Steve Jurvetson, CC BY 2.0 , via Wikimedia Commons

Tesla CEO Elon Musk just revealed more details about the company’s June Robotaxi launch, which will kick off in Austin.

As of right now, Tesla is still set to push out the first Robotaxi rides in Austin, Texas, in early June. These vehicles will be in short supply at first, as Musk says the company is purposely rolling out the fleet in a slow and controlled fashion to prioritize safety. There will be ten vehicles in the Robotaxi fleet to start.

Tesla Robotaxi deemed a total failure by media — even though it hasn’t been released

However, in an interview with CNBC on Tuesday afternoon, Musk also revealed some other new details, including where in Austin the vehicles will be able to go, how many Robotaxis we could see on public roads within a few months, and other information regarding Tesla’s Full Self-Driving suite.

A Controlled Rollout

Tesla has maintained for a few months now that the Robotaxi fleet will be comprised of between 10 and 20 Model Y vehicles in Austin.

The Cybercab, which was unveiled by the company last October, will not be available initially, as those cars will likely be produced in 2026.

Musk said during the CNBC interview that Tesla is doing a low-yield trial at first to initiate a safety-first mentality. It is important for Tesla to launch the Robotaxi fleet in a small manner to keep things in check, at least at first.

As confidence builds and the accuracy of the fleet is ensured, more vehicles will be added to the fleet.

Musk believes there will be 1,000 Robotaxis on the road “in a few months.”

Geofenced to Certain Austin Areas

Tesla will be launching the Robotaxi program in a geofenced fashion that gives the company the ability to control where it goes. Musk says that the areas the Robotaxis will be able to travel to are among the safest neighborhoods and areas in Austin.

This is yet another safety protocol that will ensure the initial riders are not put in dangerous neighborhoods.

Some might be disappointed to hear this because of Tesla’s spoken confidence regarding Robotaxi, but the initial rollout does need to be controlled for safety reasons. An accident or incident of any kind that would put riders’ lives in danger would be catastrophic.

No Driver, No Problem

As the company has rolled out an employee-only version of the Robotaxi program in Austin and the San Francisco Bay Area, some wondered whether the rides would be driverless, as these initial trials for Tesla workers were not. Employee rides featured a human in the driver’s seat to ensure safety.

Tesla says it has launched ride-hailing Robotaxi teaser to employees only

The company did not report whether there were any interventions or not, but it did state that the vehicles traveled over 15,000 miles through 1,500 trips.

Musk confirmed during the interview that there will be no driver in the vehicle when the Robotaxi program launches in June. This will be groundbreaking as it will be the first time that Tesla vehicles will operate on public roads without anyone in the driver’s seat.

Full Self-Driving Licensing

For more than a year, Tesla has indicated that it is in talks with another major automaker regarding the licensing of Full Self-Driving. Many speculated that the company was Ford, but neither it nor Tesla confirmed this.

Musk said today that Tesla has been in touch with “a number of automakers” that have inquired about licensing FSD. Tesla has yet to sign any deal to do so.

Continue Reading

Elon Musk

Elon Musk on Tesla vehicle sales: “We see no problem with demand”

“The sales numbers at this point are strong, and we see no problem with demand,” Musk said.

Published

on

(Credit: Tesla)

During a rather testy interview with Bloomberg’s Mishal Husain at the Qatar Economic Forum, Elon Musk stated that the demand for Tesla’s vehicles is still strong. Musk also stated that the issues that Tesla faced earlier his year have already turned around.

Already Turned Around

Tesla sales saw notable drops in the past months, particularly in Europe, where several countries saw drastically fewer Tesla sales year-over-year. Tesla stated in its Q1 2025 vehicle delivery report that the declines were largely due to the company’s changeover to the new Model Y, but media reports nevertheless placed the blame on Musk’s politics and his work with the Trump administration’s Department of Government Efficiency (DOGE).

It was then no surprise that Bloomberg’s Husain pointed out Tesla’s low sales in Europe this April during the interview. When questioned about the matter, Musk stated that things have “already turned around.” Musk also noted that while Tesla sales are down in Europe so far, this is true for numerous other carmakers in the region.

No Problem With Demand

When asked for evidence to back up his claims, Musk stated that Europe is indeed Tesla’s weakest market, but the company remains “strong everywhere else.” He also admitted that while Tesla has “lost some sales from the left,” the company also “gained some from the right.” Musk highlighted the fact that Tesla stock, which is partly affected by analysts with insider information, is trading at near all-time highs.

“The sales numbers at this point are strong, and we see no problem with demand. You can just look at the stock price. If you want the best insider information, the stock market analysts have that, and our stock wouldn’t be trading near all-time highs if things weren’t in good shape. They’re fine. Don’t worry about it,” Musk said. 

Advertisement

Watch Elon Musk’s full interview at the Qatar Economic Forum in the video below.

Continue Reading

Trending